- Home
- RXRX vs APLS Comparison
RXRX vs APLS Comparison
Compare RXRX & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RXRX | APLS |
|---|---|---|
| Founded | 2013 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.7B |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | RXRX | APLS |
|---|---|---|
| Price | $4.24 | $24.84 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 19 |
| Target Price | $7.25 | ★ $33.11 |
| AVG Volume (30 Days) | ★ 21.7M | 2.2M |
| Earning Date | 11-05-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.36 |
| Revenue | $43,689,000.00 | ★ $1,016,397,000.00 |
| Revenue This Year | $7.79 | $29.00 |
| Revenue Next Year | $27.32 | N/A |
| P/E Ratio | ★ N/A | $70.45 |
| Revenue Growth | N/A | ★ 42.11 |
| 52 Week Low | $3.79 | $16.10 |
| 52 Week High | $12.36 | $35.71 |
Technical Indicators
Market Signals| Indicator | RXRX | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 40.71 | 63.79 |
| Support Level | $4.61 | $24.45 |
| Resistance Level | $5.09 | $25.52 |
| Average True Range (ATR) | 0.26 | 0.93 |
| MACD | 0.02 | 0.55 |
| Stochastic Oscillator | 8.61 | 84.48 |
Price Performance
Historical ComparisonAbout RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.